SCHEMBL2887320

SCHEMBL2887320

N#Cc1c[nH]c2nccc(Cc3ccc(Nc4ccnc(N)n4)cc3F)c12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 12/20 0.64
CYP3A4 P08684 4/20 0.52
ROCK1 Q13464 5/20 0.40
CDC42BPA Q5VT25 4/20 0.40
CDC42BPB Q9Y5S2 2/20 0.40
MAPKAPK2 P49137 2/20 0.39
LRRK2 Q5S007 3/20 0.39
PRKACA P17612 2/20 0.38
PRKCD Q05655 2/20 0.38
DYRK1A Q13627 1/20 0.38
CDC7 O00311 1/20 0.38
CHEK1 O14757 1/20 0.38
AURKA O14965 1/20 0.38
PDPK1 O15530 1/20 0.38
DAPK3 O43293 1/20 0.38
DYRK3 O43781 1/20 0.38
CACNA1F O60840 1/20 0.38
RAF1 P04049 1/20 0.38
ERBB2 P04626 1/20 0.38
NTRK1 P04629 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881827 0.88 ROCK2 (0.52) ROCK2CYP3A4ROCK1CDC42BPACDC42BPB
SCHEMBL2887283 0.82 ROCK2 (0.48) ROCK2ROCK1CDC42BPACDC42BPBLRRK2
SCHEMBL4768303 0.81 ROCK2 (0.81) ROCK2CYP3A4ROCK1CDC42BPAPRKACA
SCHEMBL4774331 0.78 ROCK2 (1.00) ROCK2CYP3A4ROCK1CDC42BPAPRKACA
SCHEMBL8270533 0.73 ROCK2 (0.66) ROCK2CYP3A4ROCK1CDC42BPAPRKACA
SCHEMBL4775566 0.71 ROCK2 (0.76) ROCK2CYP3A4ROCK1CDC42BPAPRKACA
SCHEMBL5087970 0.70 ROCK2 (0.67) ROCK2CYP3A4ROCK1CDC42BPAPRKACA
SCHEMBL5097090 0.69 ROCK2 (0.72) ROCK2CYP3A4ROCK1CDC42BPAPRKACA
SCHEMBL8283994 0.68 ROCK2 (0.79) ROCK2CYP3A4ROCK1CDC42BPAPRKACA
SCHEMBL8283427 0.68 ROCK2 (1.00) ROCK2CYP3A4ROCK1CDC42BPAPRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
US-7723347-B2 Substituted phenylamino-pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-25 US disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
EP-1742945-B1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER SCHERING PHARMA AG (DE) 2009-12-30 EP disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
US-20080269268-A1 Substituted Phenylamino-Pyrimidines BAYER HEALTHCARE AG (DE) 2008-10-30 US disclosed
EP-1742945-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES Bayer HealthCare AG (DE) 2007-01-17 EP disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed
WO-2005108397-A1 SUBSTITUTED PHENYLAMINO-PYRIMIDINES BAYER HEALTHCARE AG (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269268-A1 Substituted Phenylamino-Pyrimidines TYMP, DPYD, HPRT1 ROCK2 4593/4885CYP3A4 599/4885ROCK1 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.